ATE432071T1 - Fettsäureanaloge zur behandlung von entzündungs- und autoimmunerkrankungen - Google Patents

Fettsäureanaloge zur behandlung von entzündungs- und autoimmunerkrankungen

Info

Publication number: ATE432071T1
Authority: AT; Austria
Prior art keywords: fatty acid; acid analogues; inflammatory; treatment; autoimmune diseases
Prior art date: 2000-11-28

Application number

AT01998347T

Other languages

English (en)

Inventor

Rolf Berge

Pal Aukrust

Original Assignee

Thia Medica As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-28

Filing date

2001-11-27

Publication date

2009-06-15

2001-11-27 Application filed by Thia Medica As filed Critical Thia Medica As

2009-06-15 Application granted granted Critical

2009-06-15 Publication of ATE432071T1 publication Critical patent/ATE432071T1/de

Links

235000014113 dietary fatty acids Nutrition 0.000 title abstract 2
229930195729 fatty acid Natural products 0.000 title abstract 2
239000000194 fatty acid Substances 0.000 title abstract 2
150000004665 fatty acids Chemical class 0.000 title abstract 2
208000027866 inflammatory disease Diseases 0.000 title abstract 2
208000023275 Autoimmune disease Diseases 0.000 title 1
230000002757 inflammatory effect Effects 0.000 title 1
IPBCWPPBAWQYOO-UHFFFAOYSA-N 2-(tetradecylthio)acetic acid Chemical compound CCCCCCCCCCCCCCSCC(O)=O IPBCWPPBAWQYOO-UHFFFAOYSA-N 0.000 abstract 1
LUQGQZIVDLUXLE-UHFFFAOYSA-N CCCCCCCCCCCCCCCC(O)=[Se] Chemical compound CCCCCCCCCCCCCCCC(O)=[Se] LUQGQZIVDLUXLE-UHFFFAOYSA-N 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
201000009594 Systemic Scleroderma Diseases 0.000 abstract 1
208000004732 Systemic Vasculitis Diseases 0.000 abstract 1
206010042953 Systemic sclerosis Diseases 0.000 abstract 1
206010047115 Vasculitis Diseases 0.000 abstract 1
201000001981 dermatomyositis Diseases 0.000 abstract 1
208000005987 polymyositis Diseases 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Endocrinology (AREA)
Oncology (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Virology (AREA)

AT01998347T 2000-11-28 2001-11-27 Fettsäureanaloge zur behandlung von entzündungs- und autoimmunerkrankungen ATE432071T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
NO20006008A NO20006008L (no)	2000-11-28	2000-11-28	Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer
PCT/NO2001/000470 WO2002043728A1 (en)	2000-11-28	2001-11-27	Fatty acid analogues for the treatment of inflammatory and autoimmune disorders

Publications (1)

Publication Number	Publication Date
ATE432071T1 true ATE432071T1 (de)	2009-06-15

Family

ID=19911849

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01998347T ATE432071T1 (de)	2000-11-28	2001-11-27	Fettsäureanaloge zur behandlung von entzündungs- und autoimmunerkrankungen

Country Status (17)

Country	Link
US (2)	US8088825B2 (de)
EP (1)	EP1351672B1 (de)
JP (1)	JP4368579B2 (de)
KR (1)	KR100905335B1 (de)
CN (1)	CN1296039C (de)
AT (1)	ATE432071T1 (de)
AU (2)	AU2316202A (de)
BR (1)	BR0115527A (de)
CA (1)	CA2457925C (de)
DE (1)	DE60138834D1 (de)
ES (1)	ES2326159T3 (de)
MX (1)	MXPA03004427A (de)
NO (1)	NO20006008L (de)
NZ (1)	NZ525889A (de)
RU (1)	RU2259823C2 (de)
WO (1)	WO2002043728A1 (de)
ZA (1)	ZA200303668B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NO328803B1 (no)	2000-03-03	2010-05-18	Thia Medica	Nye fettsyreanaloger
AU2003278602C1 (en)	2002-06-20	2010-08-12	Pronova Biopharma Norge As	Sulfur-containing phospholipid derivatives
JP2007522118A (ja) *	2004-01-30	2007-08-09	ペプリンバイオリピッズピーティーワイエルティーディー	治療用分子および担体分子
JP2008506773A (ja) *	2004-07-19	2008-03-06	ティアメディカアクスイェセルスカプ	タンパク質材料と非酸化性脂肪酸体を含む組成物
WO2009006668A1 (en) *	2007-02-05	2009-01-15	Children, Youth And Women's Health Service	Modulators of antigen-dependent t cell proliferation
DE102011050519A1 (de) *	2011-05-20	2012-11-22	Universität Rostock	Alkylschwefelalkansäurederivate und ihre pharmazeutisch verträglichen Salze zur Behandlung chronisch entzündlicher Erkrankungen
WO2014140934A2 (en)	2013-03-11	2014-09-18	Life Science Nutrition As	Natural lipids containing non-oxidizable fatty acids
AU2014228387B2 (en)	2013-03-11	2016-09-01	Sciadonics, Inc.	Lipid compositions containing bioactive fatty acids
AU2018354090B2 (en)	2017-10-23	2024-10-24	Epitracker, Inc.	Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome
EP3796976A4 (de)	2018-05-23	2022-03-30	Epitracker, Inc.	Zusammensetzungen und verfahren zur diagnose und behandlung von alterungs- und langlebigen bedingungen
EP3908374A4 (de)	2019-01-09	2022-12-28	Epitracker, Inc.	Zusammensetzungen und verfahren zur diagnose und behandlung von neurodegenerativen erkrankungen
JP7404382B2 (ja)	2019-03-04	2023-12-25	エピトラッカーインコーポレイテッド	脂肪酸アナログ、ならびに認知機能障害、行動症状および慢性疼痛の処置におけるそれらの使用
JP2024539823A (ja)	2021-11-03	2024-10-31	エピトラッカーインコーポレイテッド	老化の質および寿命に関係する状態の治療のためのペンタデカノイルカルニチン

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS56164120A (en) *	1980-05-22	1981-12-17	Chisso Corp	Antitumor agent
FR2631339B1 (fr) *	1988-05-10	1990-11-16	Cird	Nouveaux eicosanoides sulfures et leur application en pharmacie et en cosmetique
DE4120917A1 (de) *	1991-06-25	1993-01-07	Basf Ag	Ester von fettsaeuren mit aminoalkoholen zur verwendung bei der bekaempfung von krankheiten
US5807884A (en) *	1992-10-30	1998-09-15	Emory University	Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5618955A (en) *	1992-11-30	1997-04-08	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Fatty acid derivatives and pharmaceutical compositions containing same
IL103932A (en) *	1992-11-30	1997-02-18	Yissum Res & Dev	Fatty acid and pharmaceutical compositions containing them
CN1088058C (zh) *	1994-10-13	2002-07-24	肽技术有限公司	经修饰的多不饱和脂肪酸
NO952796D0 (no) *	1995-07-14	1995-07-14	Rolf Berge	Fettsyre analoger med ikkeoksyderbart B-sete, fremstilling og anvendelse i krapeutiske preparater
RU2089179C1 (ru) *	1995-12-14	1997-09-10	Закрытое акционерное общество "ВАМ"	Стимулятор эндогенной продукции цитокинов и гепопоэтических факторов и способ его использования
US6262119B1 (en) *	1996-04-12	2001-07-17	Peptide Technology Limited	Methods of treating immunopathologies using polyunsaturated fatty acids
IL121165A0 (en) *	1997-06-26	1997-11-20	Yissum Res Dev Co	Pharmaceutical compositions containing carboxylic acids and derivatives thereof
WO1999058120A1 (en) *	1998-05-08	1999-11-18	Rolf Berge	USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
AUPQ291499A0 (en) *	1999-09-17	1999-10-07	Women's And Children's Hospital Adelaide	Novel nitro and sulphur containing compounds

2000
- 2000-11-28 NO NO20006008A patent/NO20006008L/no not_active Application Discontinuation
2001
- 2001-11-27 BR BR0115527-0A patent/BR0115527A/pt not_active IP Right Cessation
- 2001-11-27 CN CNB018196969A patent/CN1296039C/zh not_active Expired - Fee Related
- 2001-11-27 AT AT01998347T patent/ATE432071T1/de not_active IP Right Cessation
- 2001-11-27 KR KR1020037007097A patent/KR100905335B1/ko not_active Expired - Fee Related
- 2001-11-27 CA CA2457925A patent/CA2457925C/en not_active Expired - Fee Related
- 2001-11-27 MX MXPA03004427A patent/MXPA03004427A/es active IP Right Grant
- 2001-11-27 WO PCT/NO2001/000470 patent/WO2002043728A1/en not_active Ceased
- 2001-11-27 AU AU2316202A patent/AU2316202A/xx active Pending
- 2001-11-27 EP EP01998347A patent/EP1351672B1/de not_active Expired - Lifetime
- 2001-11-27 AU AU2002223162A patent/AU2002223162B2/en not_active Ceased
- 2001-11-27 US US10/416,378 patent/US8088825B2/en not_active Expired - Fee Related
- 2001-11-27 DE DE60138834T patent/DE60138834D1/de not_active Expired - Lifetime
- 2001-11-27 ES ES01998347T patent/ES2326159T3/es not_active Expired - Lifetime
- 2001-11-27 RU RU2003115423/15A patent/RU2259823C2/ru not_active IP Right Cessation
- 2001-11-27 JP JP2002545699A patent/JP4368579B2/ja not_active Expired - Fee Related
- 2001-11-27 NZ NZ525889A patent/NZ525889A/en unknown
2003
- 2003-05-13 ZA ZA200303668A patent/ZA200303668B/en unknown
2011
- 2011-12-29 US US13/340,157 patent/US20120101161A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2457925A1 (en)	2002-06-06
KR100905335B1 (ko)	2009-07-01
ES2326159T3 (es)	2009-10-02
JP4368579B2 (ja)	2009-11-18
DE60138834D1 (de)	2009-07-09
AU2002223162B2 (en)	2006-11-30
JP2004514693A (ja)	2004-05-20
CA2457925C (en)	2013-03-26
NO20006008D0 (no)	2000-11-28
NO20006008L (no)	2002-05-29
US8088825B2 (en)	2012-01-03
CN1633284A (zh)	2005-06-29
EP1351672A1 (de)	2003-10-15
CN1296039C (zh)	2007-01-24
KR20030055322A (ko)	2003-07-02
NZ525889A (en)	2004-10-29
ZA200303668B (en)	2004-01-30
RU2259823C2 (ru)	2005-09-10
MXPA03004427A (es)	2004-05-04
EP1351672B1 (de)	2009-05-27
WO2002043728A1 (en)	2002-06-06
BR0115527A (pt)	2003-09-23
AU2316202A (en)	2002-06-11
HK1073793A1 (en)	2005-10-21
US20050165103A1 (en)	2005-07-28
US20120101161A1 (en)	2012-04-26

Legal Events

Date	Code	Title	Description
2009-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60138834D1 (de)	2009-07-09	Fettsäureanaloge zur behandlung von entzündungs- und autoimmunerkrankungen
EA199800119A1 (ru)	1998-08-27	Ингибиторы адгезии клеток
DE60035057D1 (de)	2007-07-12	CD40 Antagonist zur Behandlung von Psoriasis
ATE356113T1 (de)	2007-03-15	Probucolbernsteinsäureester zur hemmung der expression von vcam-1
DE60213404D1 (de)	2006-09-07	Verwendung von sulodexid zur behandlung von reizdarm
AP2001002217A0 (en)	2001-09-30	Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids.
FI973087A7 (fi)	1997-09-22	Soluadheesion inhibiittoreita
CY1110259T1 (el)	2015-01-14	Ανοσορυθμιστης
DE69833971D1 (de)	2006-05-11	Verfahren zur behandlung von alzheimerschen krankheit
ATE242633T1 (de)	2003-06-15	Dialkylfumarate zur behandlung von autoimmunerkrankungen
ATE473736T1 (de)	2010-07-15	Verwendung von treprostinil zur behandlung von ischämischen läsionen
DE69429450D1 (de)	2002-01-24	Die verwendung von angiotensin iii und seiner analoge für die gewebeheilung
ATE328605T1 (de)	2006-06-15	Verwendung von insulin zur behandlung von knorpelkrankheiten
DE60109938D1 (de)	2005-05-12	Zusammenstellungen die aktive stilbenoidverbindungen enthalten zur senkung des triglyceridspiegels
EE05423B1 (et)	2011-06-15	IL-18 inhibiitori kasutamine maksakahjustuse ja muude haiguste raviks v?i ennetamiseks sobiva ravimi valmistamiseks, vektori ja raku kasutamine inhibiitori produtseerimisel ning IL-18 inhibiitorit sisaldav farmatseutiline kompositsioon
DE60123238D1 (de)	2006-11-02	Zusammensetzungen zur behandlung von autoimmunkrankheiten
ATE338563T1 (de)	2006-09-15	Verfahren zur behandlung von patienten die unter multipler sklerose leiden mit konsensus- interferon
PT969843E (pt)	2002-10-31	Composicoes antitussicas contendo teobromina
DE60140960D1 (de)	2010-02-11	Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
DE60131393D1 (de)	2007-12-27	Verfahren zur behandlung von erkrankungen assoziiert mit akuten entzündung unter nichtischämischen zustände
DE69625682D1 (de)	2003-02-13	Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
DE69830586D1 (de)	2005-07-21	Verwendung von gaba analoga wie gabapentin zur herstellung eines medikaments für die behandlung von entzündungserkrankungen
DK1150698T3 (da)	2006-01-16	Anvendelser af vaskulær endotelvækstfaktor i behandlingen af erektil dysfunktion
DK1342410T3 (da)	2010-05-31	Anvendelse af en galaninagonist til fremstilling af et medikament til forbedring af hukommelse og andre kognitive funktioner
ATE161733T1 (de)	1998-01-15	Mischungen zur desodorisierung von tierexcrementen und entsprechendes verfahren zur desodorisierung